Cerenome, Inc. to Update on CNSide Diagnostics Commercial Progress
1 report, 1 independent
Updated Sep 25
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cerenome, Inc. confirmed that CNSide Diagnostics, LLC is a wholly-owned subsidiary. The company announced a conference call scheduled for September 30, 2026, to provide a business update on CNSide’s cerebrospinal fluid diagnostic platform. The update will cover third-party billing, market access, and expansion of the commercial team and testing portfolio.
From manilatimes.net
Why it matters
The update is expected to detail the commercial progress and growth strategies for CNSide’s diagnostic platform. Marc H. Hedrick, President and CEO of Cerenome, stated that the team has made significant progress since launching CNSide in early 2026 and plans to share positive developments with the capital markets community.
From manilatimes.net